Teva Pharmaceutical Industries Limited Sponsored ADR Aktie News

More than half a million bottles of Prazosin Hydrochloride have been recalled over high levels of a chemical compound that could cause cancer, the FDA said.

Added 4,306,363 Teva shares, an estimated $75.64 million trade based on the average quarterly price for Q3 2025 Transaction represents a 0.68% increase in reportable U.S. equity assets under management as of Q3 2025. Post-trade: 37,696,690 shares valued at $761.46 million as of Q3 2025.

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) marketing authorization in September 2024 Partnership brings together both companies' expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH,...

Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA-approved drugs and product candidates relative to the rival. By reading this article, you will learn which stock, Viatris or Teva, is more attractive in the long term.

Billionaire Stanley Druckenmiller has earned a spot among the best investors ever. Through more than four decades of investing, Druckenmiller has yet to post a year where his investments finished in the red, and that includes during the Great Recession in 2008-09, when his fund at the time posted an 11% gain.

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adj...

Teva Pharmaceutical Industries Limited is regaining investor interest as restructuring efforts drive margin improvements and unlock pipeline potential. Turnaround: company is changing to a more profitable company. Duvakitug and the company's other pipelines have significant future potential.

For a lot of investors, earnings season is the highlight of every quarter. It's the roughly six-week period where most S&P 500 components report their operating results and give investors an inside look at how "healthy" corporate America really is.